

ANDA 75-619

November 17, 2000

Copley Pharmaceutical Inc.,  
Attention: Deborah A. Jaskot  
1090 Horsham Road  
P.O. Box 1090  
North Wales, PA 19454

Dear Madam:

This is in reference to your abbreviated new drug application dated April 15, 1999, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (Act), for Minoxidil Topical Solution USP, 5% (For Men).

Reference is also made to your amendment dated October 20, 2000.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted Over-The-Counter (OTC) labeling. Accordingly the application is approved. The Division of Bioequivalence has determined your Minoxidil Topical Solution USP, 5% (For Men) to be bioequivalent to the listed drug [Rogaine<sup>®</sup> Extra Strength, 5% (For Men) of Pharmacia & Upjohn Co.].

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Sincerely yours,

Gary Buehler  
Acting Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research